Commentary

Video

Dr Hasan on the Preclinical Efficacy of ROR1-Specific CAR T-Cells in CLL

Md Kamrul Hasan, PhD, discusses the preclinical efficacy and safety of ROR1-specific CAR T-cells in a preclinical mouse model of chronic lymphocytic leukemia.

Md Kamrul Hasan, PhD, assistant project scientist, Department of Medicine, University of San Diego California, discusses the preclinical efficacy and safety of ROR1-specific CAR T-cells in a preclinical mouse model of chronic lymphocytic leukemia (CLL).

In this preclinical study, investigators developed a CAR T-cell construct using intracellular co-stimulatory domains (CD137 and CD3zeta), a CD28 transmembrane domain, and an IgG4 spacer region. This construct featured an anti-ROR1-scFv derived from the humanized scFv of zilovertamab. Zilovertamab (formerly UC-961/ cirmtuzumab) had previously demonstrated high affinity and a favorable safety profile in a phase 1 trial, Hasan details. The researchers employed this anti-ROR1 CAR construct to generate anti-ROR1 CAR T-cells from both healthy donors and patients with CLL. The cytotoxic activity of ROR1-CAR T-cells in both primary CLL cells and the CLL-derived mouse model was then assessed, Hasan explains.

Results showed that anti-ROR1 CAR T-cells was safe and exhibited potent cytotoxicity against autologous or allogenic primary CLL cells expressing high-risk adverse genetic features such as mutant TP53 or 17p deletions, or transfected cells expressing ROR1, Hasan reports. Notably, the cytotoxic activity of anti-ROR1 CAR T-cells was found to be specific for ROR1. This was previously demonstrated by the inhibition of killing capacity when CLL cells were pretreated with the anti-ROR1 monoclonal antibody zilovertamab.

Furthermore, researchers reported that anti-ROR1 CAR T-cells did not exhibit cytotoxic activity against normal B cells. This specificity was maintained even in co-culture with ROR1-expressing CLL cells, highlighting the potential of this approach to selectively target CLL cells without affecting normal CD19/CD20-expressing B cells.

In the immune-deficient murine model, anti-ROR1 CAR T-cells were active in eliminating ROR1-expressing cells, demonstrating their in-vivo efficacy. Investigators concluded that lentivirus encoding this anti-ROR1 CAR construct can successfully generate anti-ROR1 CAR T-cells from both healthy donors and CLL patients. These T-cells showed early efficacy when eliminating ROR1-expressing leukemia cells both in vitro and in vivo, providing a promising avenue for targeted CLL treatment with potential advantages in terms of selective killing and reduced impact on normal B cells. An evaluation of anti-ROR1 CAR T-cells in human patients is currently in development based on these results, Hasan concludes.

Related Videos
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine
Maxwell Lloyd, MD, clinical fellow, medicine, Department of Medicine, Beth Israel Deaconess Medical Center
Tracy George, MD
Elias Jabbour, MD
Bently P. Doonan, MD
Eytan M. Stein, MD
Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute
Hope S. Rugo, MD, FASCO, Winterhof Family Endowed Professor in Breast Cancer, professor, Department of Medicine (Hematology/Oncology), director, Breast Oncology and Clinical Trials Education; medical director, Cancer Infusion Services; the University of California San Francisco Helen Diller Family Comprehensive Cancer Center
Virginia Kaklamani, MD, DSc, professor, medicine, Division of Hematology-Medical Oncology, The University of Texas (UT) Health Science Center San Antonio; leader, breast cancer program, Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center
Aditya Bardia, MD, MPH, FASCO, professor, Department of Medicine, Division of Hematology/Oncology, director, Translational Research Integration, UCLA Health Jonsson Comprehensive Cancer Center